STOCK TITAN

Collplant Biotechnologies Ltd - CLGN STOCK NEWS

Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.

About CollPlant Biotechnologies Ltd.

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a pioneering regenerative and aesthetic medicine company that is transforming the landscape of tissue repair, organ manufacturing, and medical aesthetics. Utilizing its proprietary recombinant human collagen (rhCollagen) technology, produced through a unique plant-based genetic engineering process, CollPlant addresses critical challenges in regenerative medicine with innovative, biocompatible solutions. The company’s products are designed to enable tissue regeneration, reduce immune response risks, and enhance patient outcomes across diverse medical fields.

Key Technologies and Products

At the heart of CollPlant’s innovation is its rhCollagen, a plant-derived, non-animal collagen that serves as the foundation for its product portfolio. This collagen is recognized for its superior biocompatibility, safety, and ability to support tissue regeneration. The company’s flagship offerings include:

  • rhCollagen BioInk: A cutting-edge bioink tailored for 3D bioprinting of tissues and organs. This bioink is a cornerstone for advancing organ manufacturing and regenerative medicine.
  • Regenerative Breast Implants: A revolutionary solution in development, designed to regenerate natural breast tissue without eliciting immune responses. These implants target the $3 billion global breast implant market, providing a safer and more natural alternative to silicone implants.
  • Vergenix™ STR: A soft tissue repair matrix for treating tendinopathy, combining rhCollagen with platelet-rich plasma (PRP) to promote healing and tendon repair.
  • Vergenix™ FG: A wound repair matrix that accelerates the healing of acute and chronic wounds by providing a supportive scaffold for cell growth.
  • Photocurable Dermal Filler: A next-generation filler under development for the medical aesthetics market, offering tissue regeneration and superior skin lifting capacity.

Strategic Collaborations

CollPlant has established strategic partnerships with industry leaders to accelerate innovation and commercialization. Notable collaborations include:

  • AbbVie: A global commercialization agreement for dermal and soft tissue fillers, leveraging CollPlant’s rhCollagen technology and AbbVie’s expertise in aesthetics.
  • Stratasys: A joint development initiative to create bioprinting solutions for regenerative breast implants, utilizing Stratasys’ P3 technology and CollPlant’s bioinks.

Market Potential and Competitive Edge

CollPlant operates in high-growth markets, including regenerative medicine, medical aesthetics, and orthobiologics. Its unique value proposition lies in its plant-based rhCollagen, which offers significant advantages over traditional animal-derived collagen, including reduced risk of immune reactions and enhanced biocompatibility. By addressing unmet needs in tissue repair and organ manufacturing, CollPlant is well-positioned to capitalize on opportunities in multi-billion-dollar markets.

Challenges and Future Outlook

While CollPlant’s innovative technology provides a competitive edge, the company faces challenges such as scaling production, navigating complex regulatory pathways, and maintaining its financial runway. However, its strong pipeline, strategic partnerships, and focus on sustainability—evidenced by its Environmental, Social, and Governance (ESG) initiatives—underscore its commitment to long-term growth and innovation.

Conclusion

CollPlant Biotechnologies Ltd. is at the forefront of ushering in a new era of regenerative medicine. Its proprietary rhCollagen technology, coupled with strategic collaborations and a robust product pipeline, positions it as a transformative player in the fields of tissue repair, organ manufacturing, and medical aesthetics. By addressing critical unmet needs with innovative, biocompatible solutions, CollPlant is poised to make a lasting impact on global healthcare.

Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) has released its first Environmental, Social and Corporate Governance (ESG) and Sustainability Report for 2023. The report outlines the company's initiatives to adopt an ESG strategy focused on high-impact areas. CollPlant aims to enhance plant-based production, reduce emissions, and deliver safe medical solutions.

The strategy is built on three pillars: Impact on the Planet, Impact on People, and Impact on Business Conduct. CollPlant's innovative rhCollagen technology eliminates the need for animal-derived collagen, promoting more ethical and sustainable practices. The company is committed to accelerating the transition to a low-carbon footprint world and enhancing its corporate ESG practices.

CEO Yehiel Tal emphasized that CollPlant's overall strategy is driven by its vision to lead in regenerative medicine and improve global health with its collagen technology. The report serves as a foundation for sharing the company's journey, ambitions, and steps towards a sustainable future in regenerative and aesthetic medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) announced a major milestone with the successful bio-printing of 200cc commercial-size regenerative breast implants using its proprietary rhCollagen bioinks. The company also reported positive interim pre-clinical data from ongoing large-animal studies, showing promising tissue growth and neovascularization without adverse reactions. The implants are designed to regenerate breast tissue, potentially offering a safer alternative to synthetic silicone implants. Large-animal studies are ongoing, with results expected in Q4 2024 and Q1 2025, which will support future human trials and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
-
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) reported its Q1 2024 financial results and provided a corporate update. The company initiated a new large-animal study for its 3D-bioprinted breast implants in December 2023, expected to conclude in June 2024. Q1 2024 GAAP revenue was $98,000, a decrease from $433,000 in Q1 2023. Costs of revenue increased to $545,000 from $325,000, resulting in a gross loss of $447,000 compared to a gross profit of $108,000 in Q1 2023. Net loss widened to $4.2 million from $3.7 million. The company also highlighted advancements in its Environmental, Social, and Governance (ESG) initiatives and recent patent approvals in the U.S., Brazil, Israel, and Australia. Cash and cash equivalents as of March 31, 2024, stood at $23.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) announced the release of its financial results for the first quarter of 2024 on May 29, 2024, before U.S. market opening. The company will host a conference call and webcast the same day at 10:00 a.m. EDT to discuss these results and provide corporate updates.

U.S. investors can dial 1-877-407-9716, international investors can call 1-201-493-6779, and Israeli investors can dial 1-809-406-247 using Conference ID 13745964. Participants can avoid long wait times by using the Call me™ feature available 15 minutes prior to the call.

A live listen-only webcast will be available, with a replay accessible on the company's website for a period. Questions for management can be submitted via email to Dan Ferry at LifeSci Advisors up to 24 hours before the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) announces financial results for 2023, highlighting progress in dermal filler and regenerative breast implant programs. The company ended 2023 with $26.7 million in cash. Collaboration with AbbVie and Stratasys advanced, triggering milestone payments. Regenerative breast implants showed promise in large-animal studies, targeting a $2.9 billion market. Intellectual property gains and ESG efforts were also notable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) schedules conference call to discuss financial results for the full year of 2023 on April 4, 2024, at 10:00 a.m. U.S. EDT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
News
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) CEO Yehiel Tal highlights key achievements in 2023, including progress with AbbVie collaboration and Stratasys partnership. The company focuses on regenerative and aesthetic medicine, with a pipeline of innovative products like regenerative breast implants and gut-on-a-chip tissue model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) CEO to present at Octane Aesthetic Tech Forum on 3D Bioprinted Regenerative Breast Implants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
CollPlant Biotechnologies (CLGN) Initiates Pre-Clinical Trial for Regenerative Breast Implants, Aiming to Revolutionize the $2.6 Billion Market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
Rhea-AI Summary
CollPlant Biotechnologies (Nasdaq: CLGN) announced a $10 million milestone payment from partner AbbVie Inc., a $29 million cash runway, and financial results for the third quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.63%
Tags

FAQ

What is the current stock price of Collplant Biotechnologies (CLGN)?

The current stock price of Collplant Biotechnologies (CLGN) is $2.57653 as of April 2, 2025.

What is the market cap of Collplant Biotechnologies (CLGN)?

The market cap of Collplant Biotechnologies (CLGN) is approximately 29.4M.

What is CollPlant Biotechnologies Ltd. known for?

CollPlant Biotechnologies specializes in regenerative medicine, 3D bioprinting, and medical aesthetics using its proprietary recombinant human collagen (rhCollagen) technology.

What is rhCollagen, and why is it significant?

rhCollagen is a plant-derived, non-animal collagen developed by CollPlant. It offers superior biocompatibility and safety, making it ideal for tissue regeneration and reducing immune response risks.

What are CollPlant’s key products?

CollPlant’s portfolio includes rhCollagen BioInk for 3D bioprinting, regenerative breast implants, Vergenix™ STR for tendon repair, Vergenix™ FG for wound healing, and a photocurable dermal filler for aesthetics.

Who are CollPlant’s strategic partners?

CollPlant collaborates with AbbVie for dermal fillers and Stratasys for bioprinting solutions, leveraging their expertise to expand its product reach and market impact.

What markets does CollPlant target?

CollPlant operates in regenerative medicine, medical aesthetics, orthobiologics, and advanced wound care, addressing unmet needs in multi-billion-dollar markets.

What makes CollPlant’s products unique?

CollPlant’s plant-based rhCollagen technology offers enhanced biocompatibility, safety, and regenerative capabilities compared to traditional animal-derived collagen.

What is the significance of CollPlant’s regenerative breast implants?

CollPlant’s regenerative breast implants aim to replace silicone implants by regenerating natural breast tissue, addressing safety concerns and improving patient outcomes.

How does CollPlant generate revenue?

CollPlant generates revenue through product sales, licensing agreements, and milestone payments from strategic collaborations such as those with AbbVie and Stratasys.

What challenges does CollPlant face?

CollPlant faces challenges in scaling production, navigating regulatory pathways, and securing additional funding to support its innovative pipeline.

What are CollPlant’s sustainability initiatives?

CollPlant has implemented ESG initiatives, focusing on reducing its carbon footprint, promoting ethical governance, and enhancing social impact through sustainable practices.
Collplant Biotechnologies Ltd

Nasdaq:CLGN

CLGN Rankings

CLGN Stock Data

29.44M
7.65M
10.16%
12.23%
0.04%
Biotechnology
Healthcare
Link
Israel
Rehovot